Channels - APOE ε4 and Alzheimer's disease biomarkers in an American Indian community :: FRELIP Discovery

Similar Items: APOE ε4 and Alzheimer's disease biomarkers in an American Indian community

Quick Look
Evaluation of fully automated ApoE4 proteotyping for APOE ε4 genotype estimation in the FINDERI cohort
Quick Look
APOE ε4, modifiable risk factors, and dementia in community‐based older Japanese adults
Quick Look
APOE‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
Quick Look
Cerebrovascular reactivity and plasma p‐tau181 in Alzheimer's disease: Insights into APOE‐related vascular phenotypes
Quick Look
Heritability of Alzheimer's disease–related plasma biomarkers in the Amish population
Quick Look
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Quick Look
A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
Quick Look
Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature
Quick Look
The effect of treating hearing loss with hearing aids on plasma biomarkers of Alzheimer's disease and related dementias
Quick Look
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
Quick Look
The words community dwelling, Spanish‐preferring Mexican/Mexican American adults use to talk about Alzheimer's disease and genetic testing: Implications for education and outreach
Quick Look
Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
Quick Look
A diagnostic plasma omics‐biomarker for Alzheimer's disease informed by microglial single‐cell transcriptomics: A pilot study
Quick Look
Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
Quick Look
Alzheimer's disease drug development pipeline: 2026
Quick Look
Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
Quick Look
Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Quick Look
Features predicting data exclusion in imaging studies of Alzheimer's disease
Quick Look
Aβ‐ and tau‐associated neuroinflammatory signatures in Alzheimer's disease
Quick Look
White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
Quick Look
Effectiveness of Souvenaid® combined with acetylcholinesterase inhibitors on caregiver burden in Alzheimer´s disease
Quick Look
Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression
Quick Look
Apathy and resting state functional connectivity across the Alzheimer's disease continuum
Quick Look
Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum